WO2005106486A3 - Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) - Google Patents

Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) Download PDF

Info

Publication number
WO2005106486A3
WO2005106486A3 PCT/EP2005/004008 EP2005004008W WO2005106486A3 WO 2005106486 A3 WO2005106486 A3 WO 2005106486A3 EP 2005004008 W EP2005004008 W EP 2005004008W WO 2005106486 A3 WO2005106486 A3 WO 2005106486A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
dpp3
dipeptidyl
peptidase
therapeutics
Prior art date
Application number
PCT/EP2005/004008
Other languages
English (en)
Other versions
WO2005106486A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005106486A2 publication Critical patent/WO2005106486A2/fr
Publication of WO2005106486A3 publication Critical patent/WO2005106486A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une DPP3 humaine laquelle est associée aux maladies cardio-vasculaires, aux infections, aux maladies respiratoires, au cancer, aux maladies endocrinologiques, aux maladies métaboliques, aux maladies gastro-entérologiques, aux inflammations, aux maladies hématologiques, aux maladies des muscles du squelette, aux maladies neurologiques et aux maladies urologiques. L'invention concerne également des dosages d'identification de composés utiles dans le traitement ou la prévention de maladies cardio-vasculaires, d'infections, de maladies respiratoires, du cancer, de maladies endocrinologiques, de maladies métaboliques, de maladies gastro-entérologiques, d'inflammations, de maladies hématologiques, de maladies des muscles du squelette, de maladies neurologiques et de maladies urologiques. L'invention concerne également des composés se fixant à et/ou activant ou inhibant l'activité de DPP3, ainsi que des compositions pharmaceutiques renfermant ces composés.
PCT/EP2005/004008 2004-04-28 2005-04-15 Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) WO2005106486A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04010058 2004-04-28
EP04010058.8 2004-04-28

Publications (2)

Publication Number Publication Date
WO2005106486A2 WO2005106486A2 (fr) 2005-11-10
WO2005106486A3 true WO2005106486A3 (fr) 2006-02-02

Family

ID=34964622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004008 WO2005106486A2 (fr) 2004-04-28 2005-04-15 Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)

Country Status (1)

Country Link
WO (1) WO2005106486A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7219737B2 (ja) 2016-04-21 2023-02-08 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ３の定量方法および治療方法
JP7424972B2 (ja) 2017-10-25 2024-01-30 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06219989A (ja) * 1993-01-27 1994-08-09 Microbial Chem Res Found 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途
WO2003072035A2 (fr) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
US20040005563A1 (en) * 2001-06-18 2004-01-08 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06219989A (ja) * 1993-01-27 1994-08-09 Microbial Chem Res Found 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途
US20040005563A1 (en) * 2001-06-18 2004-01-08 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003072035A2 (fr) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AOYAGI T ET AL: "ENZYMATIC CHANGES IN CEREBROSPINAL FLUID OF PATIENTS WITH ALZHEIMER-TYPE DAMENTIA", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, TOKYO, JP, vol. 14, no. 2, 1993, pages 133 - 139, XP009037233, ISSN: 0912-0009 *
CHIBA TAKEHIRO ET AL: "Inhibition of recombinant dipeptidyl peptidase III by synthetic hemorphin-like peptides.", PEPTIDES (NEW YORK), vol. 24, no. 5, May 2003 (2003-05-01), pages 773 - 778, XP002342483, ISSN: 0196-9781 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 588 (C - 1271) 10 November 1994 (1994-11-10) *
SIMAGA S ET AL: "Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 3, February 1998 (1998-02-01), pages 399 - 405, XP004284955, ISSN: 0959-8049 *
YAMAMOTO YUKIO ET AL: "Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII", PEPTIDES (NEW YORK), vol. 21, no. 4, April 2000 (2000-04-01), pages 503 - 508, XP002342482, ISSN: 0196-9781 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7219737B2 (ja) 2016-04-21 2023-02-08 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ３の定量方法および治療方法
JP7424972B2 (ja) 2017-10-25 2024-01-30 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用

Also Published As

Publication number Publication date
WO2005106486A2 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006010498A3 (fr) Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2006013014A3 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2006013012A3 (fr) Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1)
WO2006013015A3 (fr) Diagnostics et therapeutique pour maladies liees a la marapsine (mpn)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase